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a b s t r a c t
Introduction: COVID-19 has had an impact on the provision of colorectal cancer care. The aim of the CRC
COVID study is to describe the changes in colorectal cancer services in the UK and USA in response to the
pandemic and to understand the long-term impact.
Methods and analysis: This study comprises 4 phases. Phase 1 is a survey of colorectal units that aims to
evaluate adherences and deviations from the best practice guidelines during the COVID-19 pandemic.
Phase 2 is a monthly prospective data collection of service provision that aims to determine the impact
of the service modifications on the long-term cancer specific outcomes compared to the national stan-
dards. Phase 3 aims to predict costs attributable to the modifications of the CRC services and additional
resources required to treat patients whose treatment has been affected by the pandemic. Phase 4 aims to
compare the impact of COVID-19 on the NHS and USA model of healthcare in terms of service provision
and cost, and to propose a standardised model of delivering colorectal cancer services for future out-
breaks.
Ethics and dissemination: This study is a service evaluation and does not require HRA Approval or Ethical
Approval in the UK. Local service evaluation registration is required for each participating centre. In the
USA, Ethical Approval was granted by the Research and Development Committee. The results of this
study will be disseminated to stakeholders, submitted for peer review publications, conference presen-
tations and circulated via social media.
Registration details: Nil.
 2020 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The COVID-19 pandemic has had a significant impact on the
provision of healthcare worldwide. As of the 29th June 2020,
COVID-19 has resulted in 311,155 confirmed cases and 43,550
deaths in the UK [1]. At a local level, hospitals have been forced
to make a number of work-force modifications and changes to
service-provision to combat the crisis and maintain standards of
care for our patients [2,3]. Face-to-face consultations have been
dissolved or minimized in favour of telephone or virtual clinics.
Provision of investigations (including CT scans and endoscopies)
have been significantly reduced and all benign surgical procedures
postponed [4,5]. Furthermore, the treatment algorithm for con-
firmed colorectal cancer cases has proved challenging.
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In the UK, over forty thousand patients are diagnosed with col-
orectal cancer each year [6]. Deviation from NICE colorectal cancer
(CRC) guidelines may lead to significantly poorer outcomes. How-
ever, the current model of cancer services delivery cannot be main-
tained, because of both resource limitation and the potential risks
to patients and staff during the pandemic. There is a lack of High
Dependency Beds, which are being utilized for COVID-19 patients.
There is the risk of exposing colorectal cancer patients (the major-
ity of whom are elderly and have significant comorbidities) to the
virus during their treatment within the hospital. Patients requiring
neo-adjuvant or adjuvant therapy are at particular risk. Finally,
staff safety must also be considered, particularly around aerosol-
generating procedures such as endoscopy and laparoscopic surgery
[4,7].
Intercollegiate General Surgery Guidance on COVID-19 outlined
general principles on the provision of a safe surgical service during
the pandemic [7]. However, there has been no specific guidance to
date on how to best modify colorectal cancer (CRC) service provi-
sion during the pandemic. In the absence of a national consensus,
the onus is on individual hospital trusts and multidisciplinary
teams to make very challenging decisions about individual patient
care. Lack of a unified approach may have important consequences
at patient and healthcare institution levels.
Delay in cancer diagnosis, or treatment due to service modifica-
tion is likely to create an increased demand in resources once the
crisis has passed. Predicting the economic impact and planning
for this is essential.
How hospitals approach the new constraints on CRC care and
allocate resources may vary between the UK and USA. It is hoped
that gaining insights from both perspectives will improve the prob-
lem solving.
2. Methods and analysis
2.1. Aims and objectives
The aim of the CRC COVID study is to describe the changes in
colorectal cancer services in the UK and USA in response to the
COVID-19 pandemic and to understand the long-term impact.
Our primary and secondary objectives relevant to each phase of
the study are listed in Table 1.
2.2. Study design
This is a multi-centre service evaluation conducted through a
research collaborative with the support of the CRC COVID Steering
Committee. All colorectal units continuing to provide cancer ser-
vices in the UK, Ireland and the USA have been invited to partici-
pate. All study and recruitment information is available on the
website crccovid.org. This service evaluation has been endorsed
by the Royal College of Surgeons of England (RCS).
This service evaluation will be carried out in 4 phases (Fig. 1).
Phase 1 uses a questionnaire to assess the modifications
adopted by each colorectal unit in order to continue provision of
the colorectal cancer services during the COVID-19 pandemic. It
has been developed using an iterative process after research of
all relevant guidelines to construct the standard against which ser-
vices would be evaluated.
The following guidelines relevant to the management of col-
orectal cancer have been used as standards for this service
evaluation:
1. NICE guidelines: Colorectal Cancer [NG151] [8];
2. NICE guideline: Suspected cancer: recognition and referral
[NG12] [9];
3. Association of Coloproctology of Great Britain & Ireland
(ACPGBI): Guidelines for the Management of Cancer of the
Colon, Rectum and Anus (2017) [10–14];
4. British Society of Gastroenterology/Association of Coloproctol-
ogy of Great Britain and Ireland/Public Health England post-
polypectomy and post-colorectal cancer resection surveillance
guidelines (2020) [15].
Informal consultations with consultants, nurse specialists and
patients have been used to develop the tool and then it has been
modified after clinician review for face validity, flow, and rele-
vance. The final instrument comprises 21 questions.
Phase 2 investigates the provision of colorectal cancer services
during the COVID-19 pandemic by evaluating the performance of
each unit against the National Bowel Cancer Audit outcomes
[16]. All centres participating in Phase 2 will be required to register
this service evaluation as per local protocol prior to commence-
ment of data collection on REDCap; this will be the responsibility
of the local lead.
Phase 3 of the study will develop a prediction model of the eco-
nomic burden of the modifications in cancer service delivery. This
model will be designed jointly by two international business
schools, based on previous publications and national statistics.
Phase 4 will evaluate and compare the impact of the COVID-19
pandemic on the NHS and the USA healthcare, using data collected
during Phase 2 and the predictive mode utilized in Phase 3. Specific
differences in modifications of CRC services will be examined.
2.3. Recruitment
Phase 1 survey has been distributed to all colorectal consultants
in the UK and Ireland through personalised emails, social media
and the RCS. The recruitment of colorectal cancer units in the
Table 1
Primary and secondary study objectives.
Phase Primary objective Secondary objectives
Phase 1 Evaluate adherences and deviations from best practice
guidelines on colorectal cancer during COVID-19
pandemic
 Describe modifications to screening process for CRC
 Describe modifications to pre-operative, intra-operative and post-oper-
ative CRC service delivery
 Demonstrate global effect of COVID-19 pandemic on CRC service provi-
sion irrespective of the type of healthcare system
 Outline consensus recommendations for sustainable modifications to
CRC services
Phase 2 Determine the impact of CRC service provision following
modifications on long-term cancer specific outcomes
compared to national standards
 Predict the impact of modifications on the incidence and prevalence of
different CRC stages in 12 months
 Plan adjustments to CRC service provision after the end of pandemic
Phase 3  Predict the costs attributable to modifications of CRC services during COVID-19 pandemic
 Predict additional resources required to treat patients whose treatment has been affected by COVID-19
Phase 4  Compare the impact of COVID-19 on the NHS and USA model of healthcare in terms of service provision and cost
 Propose a standardised model of delivering colorectal cancer services for future outbreaks
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USA will use similar approach. All units recruited into Phase 1 are
recruited into Phase 2. Participation in Phase 1 is not mandatory in
order to participate in Phase 2.
2.4. Data collection
All surveys and data collection follow the GDPR requirements
and comply with Caldicott principles. Individual patient identifi-
able data is not collected in this study. Study data is collected
and managed using REDCap electronic data capture tool hosted
at The Kennedy Institute of Rheumatology at the University of
Oxford [17,18]. REDCap (Research Electronic Data Capture) is a
secure, web-based software platform designed to support data
capture for research studies, providing 1) an intuitive interface
for validated data capture; 2) audit trails for tracking data manip-
ulation and export procedures; 3) automated export procedures for
seamless data downloads to common statistical packages; and 4)
procedures for data integration and interoperability with external
sources [17,18].
After the close of the Phase 2 data collection period, all data sets
will be checked for missing data. Where possible, centres will be
given an opportunity to rectify missing data. Centres where >5%
of data is missing will be excluded from data analysis and local
leads will be notified. A nominated data validator will need to
ensure data accuracy prior to submission. If during this process
major discrepancy is identified within the data set, the centre’s
data will be excluded completely from the analysis.
For details of the data collected in Phase 1 and Phase 2, please
refer to Supplement 1.
2.5. Data analysis
Phase 1: Responses to the survey pertaining to deviations from
diagnostic and treatment protocols during the COVID-19 pandemic
(see Supplement 1) will be converted to a numerical scale, where 0
will denote no deviation and 1 will denote complete cessation of
service provision. The scores will be summarized using appropriate
summary statistics and analyzed using unsupervised learning
(k-means and hierarchical clustering) to identify clusters of homo-
geneous response to the pandemic.
Phase 2: Every month participating centres will report their
diagnostic and treatment activity (see Supplement 1). To deter-
mine the impact of COVID-19 on colorectal cancer activity we will
use time-series methods and data on historical activity and patient
outcomes [19,20] to estimate a baseline of expected monthly activ-
ity that would have taken place in the absence of the pandemic.
The baseline and a 95% confidence interval will be estimated at
the national, regional, and individual NHS trust level. The baseline
estimate will then be compared to the actual activity as reported
by publicly available data [19] and data collected by this study.
The difference between expected and actual activity will provide
an estimate of the reduction in activity.
To quantify the impact on patient outcomes associated with the
estimated reduction in activity and deviation from standardized
care protocols we will use estimates of disease progression avail-
able in peer-reviewed literature [21–28]. A similar methodology
will be used to predict the impact of the pandemic on the incidence
and prevalence of different colorectal cancer stages in the follow-
ing 12 months under different scenarios. Predictions will be made
at the regional and national level, and depending on data granular-
ity, at the trust level.
Phase 3 will estimate the financial costs of modifications to the
CRC service provision due to the COVID-19 pandemic. This will
allow prediction of the expenditure and the additional resources
required to resume routine services. We will base this on the liter-
ature regarding the price of treatment at different disease stages
[21] and the information about the cost of resource utilization
(consultations, diagnostic tests, operating theatre time and hospi-
tal stay). Phase 4 will compare the results from phases 1–3 in the
UK with those in the US.
3. Discussion
Cancer care and maintaining high standards of diagnosis and
treatment has long been a priority of the NHS and international
health care systems. The pandemic has shifted this focus away
from the cancer services. Colorectal cancer patients are particularly
Fig. 1. Phases of CRC COVID.
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vulnerable to the disruption of their care as diagnosis through
endoscopy was stopped due to concerns about virus aerosolysation
[4]. This study is important because it is the first study to ask how
individual units had to modify their services and adapt to the new
constraints.
In addition to describing the changes and understanding
whether different units had different approaches, we wish to go
further by understanding the effects of diagnostic and treatment
delay by prospective data collection of cancer cases, referrals diag-
nosis, staging and treatment and comparing them to nationally col-
lected audit data [16].
These data will allow us to model the economic impact of the
delay and what resources are required to restore cancer services
to pre-COVID-19 standards.
The strengths of this study are in the multi-modal approach to
the issues, international collaboration and support from the Royal
College of Surgeons. Our diverse team of management and busi-
ness academics, colorectal surgeons, nurse specialists and patient
advisors enable us to have a range of approaches to collect and
analyse the data.
The main limitation to the study is non-responder or sampling
bias as we require voluntary participation from colorectal teams.
We will ensure that we adjust statistical analysis for any under-
representation. We expect that even with minimal participation,
useful models can be generated to understand future resource
requirements at an individual hospital level. The methodology
employed by other units will demonstrate the utility of the model.
In summary this is a novel and important multi-phase study
that is vital to understand how to best care for cancer patients
and ensure that the effects of the pandemic are mitigated.
4. Ethics and dissemination
This study is a service evaluation and does not require HRA
Approval or Ethical Approval in the UK. Departmental approval
has been granted by the university. Each participating centre must
seek local permission from their local audit department prior to
commencement of data collection. In the USA, Ethical Approval
was granted by the Research and Development Committee.
Data for Phase 1 will be submitted for publication as soon as the
results become available. Interim data analysis will be presented to
the Royal College of Surgeons COVID-19 research collaborative.
Data for other phases will be submitted for publication once the
data collection has been completed, which is anticipated to be after
the routine service provision resumes. All data will be presented at
national and international conferences, circumstances permitting.
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